Integra LifeSciences Holdings Corporation

IART Healthcare Medical Devices

Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 101.0%, free cash flow grew 193.5% and total debt rose 1.51%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

13.21 0.32 −2.37%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
26.1×
Dividend yield
—
F-score
5/9
Altman Z
0.62
Beneish M
−3.25
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Revenue
992.08 1,188.24 1,472.44 1,517.56 1,371.87 1,542.45 1,557.67 1,541.57 1,610.53 1,635.25
Revenue Growth
12.39% 19.77% 23.92% 3.06% (9.60%) 12.43% 0.99% (1.03%) 4.47% 1.53%
Gross Profit
642.99 752.73 900.95 952.88 851.03 944.64 970.31 884.74 882.06 831.62
Operating Income
115.34 44.80 111.00 93.76 151.37 197.23 238.92 111.53 28.41 (493.37)
EBT
90.41 11.39 57.40 60.10 93.52 214.68 213.89 81.07 (18.24) (563.50)
Income after Tax
74.56 64.74 60.80 50.20 133.89 169.08 180.55 67.74 (6.94) (516.47)
Net Income Common
74.56 64.74 60.80 50.20 133.89 169.08 180.55 67.74 (6.94) (516.47)
EPS (Diluted)
0.94 0.82 0.72 0.58 1.57 1.98 2.16 0.84 (0.09) (6.74)
Shares (Diluted, Weighted)
79.19 79.12 84.00 86.49 85.23 85.49 83.52 80.34 77.01 76.67
Gross Margin
64.81% 63.35% 61.19% 62.79% 62.03% 61.24% 62.29% 57.39% 54.77% 50.86%
EBIT Margin
11.63% 3.77% 7.54% 6.18% 11.03% 12.79% 15.34% 7.23% 1.76% (30.17%)
Net Profit Margin
7.52% 5.45% 4.13% 3.31% 9.76% 10.96% 11.59% 4.39% (0.43%) (31.58%)
Free Cash Flow Margin
6.99% 6.00% 8.31% 10.67% 12.29% 17.14% 14.98% 4.74% 0.93% (2.77%)
EBITDA
190.53 136.47 228.00 208.61 294.89 324.10 364.06 241.20 174.90 (335.93)
EBIT
115.34 44.80 111.00 93.76 151.37 197.23 238.92 111.53 28.41 (493.37)

Show all line items

In millions of $ except per-share values · columns are period end dates